Last reviewed · How we verify
NCT05659602
A Clinical Study to Assess Preliminary Efficacy, Safety and Tolerability of HH-120 Nasal Spray in COVID-19 Patients
NA trial testing HH-120 Nasal Spray in Coronavirus Disease 2019(COVID-19) in 111 participants. Completed in 3 January 2023.
3 January 2023
Quick facts
| Lead sponsor | Beijing Ditan Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 111 |
| Start date | 9 July 2022 |
| Primary completion | 3 January 2023 |
| Estimated completion | 3 January 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- HH-120 Nasal Spray — full drug profile →
Conditions studied
- Coronavirus Disease 2019(COVID-19) — all drugs for Coronavirus Disease 2019(COVID-19) →
Sponsor
Beijing Ditan Hospital
Who can join
Adults 18 to 65, any sex, with Coronavirus Disease 2019(COVID-19). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the preliminary efficacy and safety of HH-120 nasal spray in the treatment of asymptomatic or mild COVID-19.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Broadly Effective ACE2 Decoy Proteins Protect Mice from Lethal SARS-CoV-2 Infection.
Lu M, Yao W, Li Y, Ma D, et al · · 2023 · cited 6× · PMID 37395664 · DOI 10.1128/spectrum.01100-23 -
Broadly effective ACE2 decoy proteins protect mice from lethal SARS-CoV-2 infection
Lu M, Yao W, Li Y, Ma D, et al · · 2023 · DOI 10.1101/2023.02.22.529625
Verify or expand the search:
- PubMed search for NCT05659602
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of HH-120 Nasal Spray
Trials testing the same drug.
- NCT05787418 — HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2 · Phase 3 · enrolling by invitation
- NCT05747677 — A Study of HH-120 Nasal Spray in Close Contacts of Those Diagnosed With COVID-19 · NA · completed
Other Beijing Ditan Hospital trials
Trials by the same sponsor.
- NCT06642740 — Study on the Efficacy and Safety of Avatricopal in Patients With CLD Complicated With Thrombocytopenia · enrolling by invitation
- NCT06777173 — Clinical Study of Antiviral Therapy Combined With Novel Immunotherapy for CHB in Adults · NA · enrolling by invitation
- NCT05929963 — Observational Study of the Interaction Between Hepatitis C Virus Infection and Pregnancy · unknown
- NCT05812612 — UDCA in the Treatment of COVID-19 Infection and Its Clinical Prognosis in Patients With Autoimmune Liver Disease · unknown
- NCT05765279 — A Study to Assess the Efficacy of HH-120 Nasal Spray for Prevention of SARS-CoV-2 Infection in Adult Close Contacts of I · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05659602 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Ditan Hospital
- Last refreshed: 10 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05659602.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing